Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Deferred Tax Liability: 2013-2022

Historic Non-Current Deferred Tax Liability for Amicus Therapeutics (FOLD) over the last 9 years, with Dec 2022 value amounting to $4.9 million.

  • Amicus Therapeutics' Non-Current Deferred Tax Liability rose 0.18% to $4.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.9 million, marking a year-over-year increase of 0.18%. This contributed to the annual value of $4.9 million for FY2022, which is 0.18% up from last year.
  • As of FY2022, Amicus Therapeutics' Non-Current Deferred Tax Liability stood at $4.9 million, which was up 0.18% from $4.9 million recorded in FY2021.
  • Over the past 5 years, Amicus Therapeutics' Non-Current Deferred Tax Liability peaked at $6.5 million during FY2018, and registered a low of $4.9 million during FY2020.
  • Its 3-year average for Non-Current Deferred Tax Liability is $4.9 million, with a median of $4.9 million in 2021.
  • In the last 5 years, Amicus Therapeutics' Non-Current Deferred Tax Liability decreased by 21.87% in 2019 and then grew by 0.69% in 2021.
  • Amicus Therapeutics' Non-Current Deferred Tax Liability (Yearly) stood at $6.5 million in 2018, then declined by 21.87% to $5.1 million in 2019, then fell by 3.07% to $4.9 million in 2020, then rose by 0.69% to $4.9 million in 2021, then increased by 0.18% to $4.9 million in 2022.